The Yale Stem Cell Core now provides service producing iPSC.
Reprogramming fully differentiated somatic cells to induced pluripotent stem cells (iPSCs) is used to model human disease in vitro and holds great promising in regenerative medicine. The Yale hESC/iPSC Core Facility provides services for reprogramming differentiated cells into induced pluripotent cells using two non-integration techniques in defined media and feeder-free conditions. The technique can be either Sendai virus or episomal vectors. The source cells can be fibroblasts or peripheral blood mononuclear cells. Although we do accept live cells, we prefer frozen vials with the fibroblasts at a low passage number (approximately 3 passages). Total cell numbers needed are about 1 million cells per frozen vial. For cells that have been derived directly from patients, Principal Investigators are required to provide documentation from a certified laboratory that the cells have been tested and found to be negative for HIV, Hepatitis B and Hepatitis C.
The service takes from 3 to 5 months to complete and the cost is $2,756.55 per iPSC line for Yale University investigators. This includes delivery of at least 3-5 clones, each with 3 cryopreserved vials. SSEA4 staining will be included in the delivery package. Further characterizations such as gene expression profile, karyotyping and/or teratoma formation, often used to characterize the pluripotency of iPSC cell lines, can be added at additional cost.
If you are interested in this service, please feel free to contact: